<DOC>
	<DOCNO>NCT01369589</DOCNO>
	<brief_summary>The primary objective clinical study determine impact P-552 oral rinse salivary volume administration single dose P-552and versus vehicle rinse . Changes oral mucosal wetness assess via collection salivary output via measurement oral wetness use Periotron 8000 instrument .</brief_summary>
	<brief_title>An Evaluation Impact Single Dose P-552 Oral Mucosal Wetness</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>1 . Males female , age 18 year old , capable provide write informed consent participate study . 2 . Male subject must either sexually active , surgically sterilize , agree use appropriate `` doublebarrier '' method ( diaphragm condom ) study participation least 30 day completion dose . 3 . Nonpregnant female subject must either sexually active , postmenopausal , surgically sterilize ; agree use appropriate `` doublebarrier '' method ( diaphragm condom ) ; currently use prescribe transdermal , injection , implant , oral contraceptive least 30 day receive first dose study drug study participation least 30 day completion dose . 4 . Are good health , determine medical history , physical examination , detailed oral examination , result clinical chemistry , hematology urinalysis . 5 . Has minimal level unstimulated whole mouth salivary flow ( great equal 0.05 milliliter [ i.e. , 0.05 gram ] per 5 minute ) screen visit . 6 . Have diagnosis primary Sjogren 's syndrome consistent revise version European criterion propose AmericanEuropean Consensus Group European Cooperative Community Classification Criteria Sjogren 's Syndrome . 1 . Regularly us antihistamine start dose adjust within last 30 day . 2 . Has start use systemic cholinergic secretagogues tricyclic antidepressant drug within 12 week Screening , stable dose regimen least 14 day prior Screening visit , unable maintain stable dose throughout study . 3 . Is unable withhold use systemic cholinergic secretagogues oral comfort agent ( e.g. , OraMoist , MouthKote , Biotene product , etc . ) morning study visit 2 hour dose study visit ; unable take last nighttime dose standard time throughout study . 4 . Is unable maintain stable dosage regimen concomitant medication throughout duration trial . 5 . Shows evidence significant active ongoing oral infection oral condition ( e.g. , lichen planus ) , opinion investigator , might affect safety subject might exacerbate study participation . 6 . Has acutely infect salivary gland ( without pain ) suspect closure salivary gland . 7 . Has receive investigational drug within past 30 day . 8 . Has history allergy medicine chemically related study drug ( e.g. , amiloride , Moduretic , Midamor , triamterene ) . 9 . Has present history clinically significant uncontrolled neurologic , gastrointestinal , renal , hepatic , cardiovascular ( include hyper/hypotension tachy/bradycardia ) , psychological , pulmonary , metabolic , endocrine , hematological disorder disease , major disorder disease , opinion investigator . 10 . Has viral hepatitis test positively hepatitis B surface antigen hepatitis C ( nonA , nonB ) antibody , positive result human immunodeficiency virus antibody . 11 . Has positive serum pregnancy test nursing ( female subject ) . 12 . Should participate study , opinion Principal Clinical investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Xerostomia</keyword>
	<keyword>dry mouth</keyword>
	<keyword>Sjogren 's Syndrome</keyword>
</DOC>